Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov 27:13:335.
doi: 10.1186/1472-6882-13-335.

KM110329 in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, multicentre trial--study protocol

Chunhoo Cheon  1 , Sunju Park, Jeong-Su Park, So-Mi Oh, Soobin Jang, Ho-Yeon Go, Bo-Hyoung Jang, Yong-Cheol Shin, Seong-Gyu Ko
Affiliations
Randomized Controlled Trial

KM110329 in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, multicentre trial--study protocol

Chunhoo Cheon et al. BMC Complement Altern Med. .

Abstract

Background: Atopic dermatitis is a chronic inflammatory skin disease with a high prevalence rate and a large socioeconomic cost. There are many treatments for atopic dermatitis, such as antihistamine, tacrolimus and corticosteroids. However, due to concern about the adverse effects, many patients seek alternative treatments. In this context, natural products are gaining interest. KM110329 is a functional food consisting of four herbs that are beneficial to skin health. The purpose of this study is to assess the efficacy and safety of KM110329 for atopic dermatitis.

Methods/design: This study is a randomised, double-blind, placebo-controlled and multicentre trial of KM110329. For this study, we will recruit 66 atopic dermatitis patients of both sexes, with ages ranging from 18 to 65, from three university hospitals. The participants will receive either KM110329 or a placebo twice a day for 8 weeks. The primary end point will be a change in the scoring atopic dermatitis (SCORAD) index. The secondary end points will include changes to the dermatology life quality index (DLQI) and transepidermal water loss (TEWL), among others. The outcomes will be measured at every visit. The study will be continued for 8 weeks and will include five visits with each subject (at screening and at 0, 1, 4 and 8 weeks).

Discussion: This trial will provide research methodologies for evaluate clinical efficacy and safety of KM110329 in adult patients with atopic dermatitis. In addition, we will evaluate the changes in the general skin health status and quality of life.

Trial registrations: ClinicalTrials.gov NCT01692093.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow chart.
See this image and copyright information in PMC

References

    1. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J. et al.Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy. 2006;61:969–987. doi: 10.1111/j.1398-9995.2006.01153.x. - DOI - PubMed
    1. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005;352:2314–2324. doi: 10.1056/NEJMcp042803. - DOI - PubMed
    1. Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2012;27:239–242. - PubMed
    1. Boo YM, Seo BI, Lee JH, Choi HY, Kwon DY. Herbology. Seoul, Korea: Younglimsa; 2011.
    1. WHO Western Pacific Region. WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region. Manila, Philippines: WHO; 2007.

Publication types

Substances

Associated data